Bell Co Health District Temple clinic to close temporarily
Temple, Tx (FOX44) – Bell County Public Health District says there will be a temporary closure of their Temple Clinic located at 820 N. 31st Street, Temple beginning June 2, 2025.
The closure is due to what were termed ' unforeseen circumstances' that are significantly impacting the district's funding.
All health district services will continue at their Killeen location. Immunization services will continue at Belton and Killeen centers. Offsite clinics for immunizations will be available upon request throughout the county.
Clinic Services at the BCPH Killeen location (309 N. 2nd St, Killeen, TX 76541) are available 7:00am-4:30pm Monday-Thursday walk-ins welcome, appointments available call (254) 532-9800 x 1604:
STI/STD/HIV testing
TB Program Management
Birth Control Services for previous patients (call in advance to check eligibility)
Immunization Services (vaccines) at the Killeen and Belton locations:
Tuesdays in BCPH Killeen office (309 N. 2nd St, Killeen, TX 76541)
7:00 am-11:00 am walk in basis (as capacity allows) and from 1:00 pm-3:00 pm by appointment only call (254) 532-9800 ext 1604
Wednesdays in BCPH Belton office (1605 N. Main St, Suite 104, Belton, TX 76513)
7:00 am-11:00 am walk in basis (as capacity allows) and from 1:00 pm-3:00 pm by appointment only call (254) 532-9800 ext 1404
Organizations can contact BCPH Immunizations at (254) 532-9800 ext 1404 to schedule offsite clinics for Mondays and Thursdays.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hamilton Spectator
4 hours ago
- Hamilton Spectator
Doctors, health experts call on N.S. to cover birth control and HIV-prevention drug
HALIFAX - Nova Scotia physicians and other sexual health experts are calling on the provincial government to fund birth control and increase access to a medication used to prevent HIV. Four doctors, the head of the Halifax Sexual Health Centre, and a pharmacy professor made the comments today at a legislature committee hearing in Halifax. Abbey Ferguson with the Halifax Sexual Health Centre says PrEP — an antiviral medication that prevents HIV transmission — is so expensive that many people who would benefit from the drug are not able to take it. The drug is estimated to cost between $200 and $250 per month. Dr. Melissa Brooks, the medical co-director of the Reproductive Options and Services Clinic, says the province's pharmacare plan is so restrictive that it often doesn't help those who cannot afford their preferred birth control option. Kari Ellen Graham, with Access Now Nova Scotia, urged the provincial government to sign on to the federal government's pharmacare program, which helps fund birth control. So far only P.E.I., Manitoba, British Columbia, and the Yukon have signed up to the federal pharmacare program. This report by The Canadian Press was first published June 10, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Yahoo
6 hours ago
- Yahoo
US aid cuts threaten South Africa's status as powerhouse of HIV and tuberculosis research
South Africa risks losing its status as a powerhouse of HIV and tuberculosis research as sweeping American funding cuts jeopardise dozens of experimental trials. At least 27 HIV trials and another 20 TB trials in the country have been put at risk by Donald Trump's deep cuts to foreign assistance and global health spending, new analysis shows. Loss of the trials would hit research projects looking for new vaccines into both infections, as well as new long-lasting protective medicines and studies into the best way to treat children. Having intense HIV and TB epidemics as well as world class universities and research institutes has made South Africa a leader in combating the two diseases. Yet while the research has often been led by South African scientists, it has overwhelmingly been conducted with international funding, particularly with 20 years of generous United States government aid spending. Prof Salim Abdool Karim, director of the Centre for the Aids Program of Research in South Africa, said: 'The US is such a big player in our country – South Africa is a powerhouse in medical research because of what the US spends.' The bulk of funding for research came from the US National Institutes of Health (NIH), with the country receiving an estimated £111m ($150m) each year. Prof Ntobeko Ntusi, the president and chief executive of the South African Medical Research Council (SAMRC), said earlier this year: 'In many ways the South African health research landscape has been a victim of its own success, because for decades we have been the largest recipients of both [official development assistance] funding from the US for research [and] also the largest recipients of NIH funding outside of the US.' Now, unless alternative sources of money can be found, South African academic and research institutes could lose about 30 per cent of their annual income and may be forced to lay off hundreds of staff, the analysis found. 'There's been a huge dependence on US funding. The loss of it for South Africa means the cancellation of a huge amount of research,' said Tom Ellman, director of the MSF's Southern Africa Medical Unit (SAMU). The joint analysis by Treatment Action Group (TAG) and Doctors Without Borders (MSF) of NIH-funded research found 39 TB and HIV clinical research sites are under threat, placing at least 27 HIV trials and 20 TB trials at risk. The effect of cuts could be wider still, with research also funded through other US channels, including the US President's Emergency Plan for Aids Relief (Pepfar), which has been slashed by Donald Trump's administration. Lindsay McKenna, TB project co-director of TAG said: 'Public funding from the US government to South Africa is the scaffold on which pharmaceutical companies, philanthropies, and other governments invest in transformative TB and HIV science.' 'These ongoing funding disruptions by the US government don't just affect US-funded research projects, they put in peril a much wider ecosystem of global research.' Dr Ellman said a combination of the infections found in South Africa, its research base and its strong grass roots activism had combined, with US funding, to make the country so prominent in research. He said: 'For years, South Africa has spearheaded the research and development of critical innovative medical tools for the prevention, diagnosis, treatment and care of HIV and TB which have saved lives not just within South Africa's borders, but also in communities worldwide.' The country has more HIV patients than any other, with an estimated 8 million currently infected and 105,000 deaths annually. The high prevalence of HIV goes hand-in-hand with a high prevalence of tuberculosis, because TB takes advantage of patients' weakened immune systems. Tuberculosis is the biggest cause of death among those with HIV in South Africa, which recorded 54,000 TB deaths in 2023. At the same time, the country has strong research institutions and universities, and a history of medical innovation, including conducting the first heart transplant in 1969. Finally, the history of the apartheid struggle, and later the fight in the early 2000s to get antiretroviral drugs in the face of government AIDS denialism, has produced well-organised and politically-engaged health activists. According to the joint analysis, HIV trials now at risk include studies into using broadly neutralising antibodies (bNAbs) to find a cure, and also trials into long-lasting anti-HIV preventative jabs. The Brilliant Consortium, a collaboration of African researchers led by the SAMRC working to develop an HIV vaccine, lost all funding even as it was about to begin an early stage vaccine trial. Dr Ellman said: 'I think it would be a disaster if we gave up on the hope of finding an effective vaccine for HIV. All of that has been done with South Africa and without access to South African research and communities, it's not going to be possible.' The emergence of some resistance to antiretroviral drugs has also highlighted the importance of trials to find new drugs which can deal with the phenomenon. HIV trials are also looking at honing and improving existing treatment regimes, as well as simplifying and rolling out expensive techniques first used in the developing world. TB trials at risk include studies for new drugs and shorter, safer regimens for treatment and prevention. The cuts have a ripple effect beyond individual trials, because they also weaken research infrastructure which is used and relied on by other funders. That could have a knock-on effect on trials looking at new TB jab possibilities, including the promising new M72/AS01E vaccine candidate. South Africa is now scrabbling for alternative sources of funding to try to salvage as many of the research projects as possible. Dr Ellman said: 'We call on all potential donors to step up, as without sustained investment, we will never end these deadly epidemics.' Protect yourself and your family by learning more about Global Health Security Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
6 hours ago
- Yahoo
US FDA pauses Gilead trials testing experimental HIV pill combination
By Sneha S K (Reuters) -The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV treatments due to low levels of a type of white blood cell in some patients, the company said on Tuesday. Shares of the company, a global leader in HIV drugs, were down 2.3% at $110.35. The agency placed the trials on hold after some patients who received the combination of the drugs, GS-1720 and GS-4182, were found to have low levels of a type of white blood cell called CD4+T-cell, the company said. Gilead did not provide more information on what caused the decline in the type of white blood cell, which is a key measurement in HIV management and serves as a guide for treatment. The company said it plans to investigate and will work with regulatory authorities to resolve the issues. The paused trials included two mid-to-late studies, and three more in the early phase, the company said. The mid-to-late stage trials were testing the oral combination treatment against Biktarvy, Gilead's once-a-day pill to treat HIV. "Today's update underscores the difficulties of improving upon the profile of Gilead's once-daily Biktarvy," said BMO Capital Markets analyst Evan Seigerman. GS-4182 is an experimental pill version of the company's approved HIV drug lenacapavir, while GS-1720 is a once-weekly therapy in development for treatment of HIV. The company said the hold is not related to Gilead's application seeking FDA's approval for lenacapavir in preventing HIV. The agency is set to decide on the application by June 19. The FDA had approved lenacapavir for HIV treatment in 2022 and is sold under the brand Sunlenca. Gilead has multiple other long-acting oral and injectable HIV treatment combinations under development, and this clinical hold does not impact those combinations, the drugmaker said.